Arsenic-containing traditional Chinese medicine Qinghuang Powder pro-tocol in the treatment of elderly high-risk myelodysplastic syndrome ac-companied by TP53 mutation:a case report and literature review
Myelodysplastic syndrome(MDS)is a clonal,myeloid tumor disease originating from hematopoietic stem cells.Its associated subtypes of increased primordial cells and mutations in tumor protein 53(TP53)gene are associated with stratified prognosis in high-risk diseases.TP53 gene mutation is also associated with treatment resistance.Elderly MDS patients have decreased organ function,multiple comorbidities,infeasible transplantation,most cannot tolerate chemotherapy,and demethylated drug treatment.Patient is an extremely elderly male diagnosed with MDS accompanied by type Ⅰ increase in primordial cells.At initial diagnosis,whole blood cells progressively decreased and blood transfusion support is required.Revised international prognostic scoring system is extremely high-risk,accompanied by TP53 gene mutation.Compared with similar patients,the use of arsenic-containing traditional Chinese medicine Qinghuang Powder protocol median survival period,improves blood count to varying degrees,improves quality of life,and does not cause treatment-related adverse reactions,with good tolerability,and achieves treatment goal of improving quality of life and prolonging survival for elderly MDS patients.This article reviews patient's clinical data and treatment process using arsenic-containing traditional Chinese medicine Qinghuang Powder protocol,and analyzes clinical characteristics,treatment methods and related gene mutation characteristics of elderly MDS in combination with relevant domestic and foreign literature,so as to provide reference for the treatment of elderly or ultra elderly MDS patients with poor prognosis.
Myelodysplastic syndromeElderlyTumor protein 53 gene mutationArsenic-containing traditional Chinese medicine Qinghuang Powder protocol
万方数据
维普
